Eyre, TA; Kirkwood, AA; Wolf, J; Hildyard, C; Mercer, C; Plaschkes, H; Griffith, J; ... Hatton, CSR; + view all Eyre, TA; Kirkwood, AA; Wolf, J; Hildyard, C; Mercer, C; Plaschkes, H; Griffith, J; Fields, P; Gunawan, A; Oliver, R; Booth, S; Martinez-Calle, N; McMillan, A; Bishton, M; Fox, CP; Collins, GP; Hatton, CSR; - view fewer (2019) Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. British Journal of Haematology , 187 (2) pp. 185-194. 10.1111/bjh.16070.

Preview	Text Kirkwood Manuscript BJH-2019-00537 R1 AK.pdf - Accepted Version Download (582kB) | Preview
Preview	Text Kirkwood Tables CNS PD elderly manuscript AK 30042019.pdf - Accepted Version Download (633kB) | Preview
Preview	Text Kirkwood Supplementary Tables CNS prophylaxis in elderly R1 AK.pdf - Accepted Version Download (440kB) | Preview
	Slideshow Figure 1 for CNS relapse paper R1 Black and White.ppt - Accepted Version Download (477kB)
	Slideshow Supplementary Figure 1.pptx - Accepted Version Download (4MB)
	Slideshow Supplementary Figure 2.pptx - Accepted Version Download (315kB)

Abstract

Central nervous system (CNS) relapse following R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) occurs in 2–5% of patents with diffuse large B‐cell lymphoma (DLBCL). Many patients aged ≥70 years are unsuitable for high‐dose methotrexate (HDMTX) prophylaxis and therefore often receive stand‐alone intrathecal prophylaxis. The CNS international prognostic index (CNS‐IPI) is a clinical CNS relapse risk score that has not specifically been validated in elderly patients. The value of CNS prophylaxis in patients aged ≥70 years remains uncertain. Data on 690 consecutively R‐CHOP‐treated DLBCL patients aged ≥70 years were collected across 8 UK centres (2009–2018). CNS prophylaxis was administered per physician preference. Median age was 77·2 years and median follow‐up was 2·8 years. CNS‐IPI was 1–3 in 60·1%, 4 in 23·8%, 5 in 13·0% and 6 in 3·3%. Renal and/or adrenal (R/A) involvement occurred in 8·8%. Two‐year overall CNS relapse incidence was 2·6% and according to CNS‐IPI, 1–3:0·8%, 4:3·6%, 5:3·8% and 6:21·8%. Two‐year CNS relapse incidence for R/A was 10·0%. When excluding HDMTX (n = 31) patients, there remained no change in unadjusted/adjusted CNS relapse for intrathecal prophylaxis effect according to CNS‐IPI. CNS‐IPI is valid in elderly R‐CHOP‐treated DLBCL patients, with the highest risk in those with CNS‐IPI 6 and R/A involvement. We observed no clear benefit for stand‐alone intrathecal prophylaxis but observed an independent increased risk of infection‐related admission during R‐CHOP when intrathecal prophylaxis was administered.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as JSONXMLCSV

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item